H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Exicure (XCUR) today and set a price target of $8.00. The company’s shares closed last Friday at $2.45.
According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 34.9% and a 66.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Inovio Pharmaceuticals.
Currently, the analyst consensus on Exicure is a Strong Buy with an average price target of $10.67, implying a 346.4% upside from current levels. In a report issued on March 12, Chardan Capital also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.30 and a one-year low of $0.96. Currently, Exicure has an average volume of 655.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
